Bharat Parenterals Q3FY26 Results Show Mixed Performance

Bharat Parenterals reported Q3FY26 standalone revenue of ₹41.41 crore, down 38.5% YoY, with net profit at ₹1.95 crore. Company maintains order book of ₹303 crore for future execution.

Bharat Parenteral Q2 FY26 Revenue Falls 35% to Rs 41.7 Crores Despite Margin Expansion

Bharat Parenteral Limited reported standalone revenue of Rs 41.7 crores in Q2 FY26, down from Rs 64.5 crores in Q2 FY25, primarily due to planned production upgrades and deferred export dispatches. The company maintained its FY26 guidance of 12-14% revenue growth with EBITDA margins of 15-17%, while subsidiary Innoxel achieved US FDA approval and signed 7 new partnerships worth $1.85 million.

Bharat Parenterals Reports 35% Revenue Decline in Q2FY26, Maintains Full-Year Growth Guidance

Bharat Parenterals Limited reported revenue from operations of ₹41.7 crore in Q2FY26, down 35% year-on-year from ₹64.5 crore in Q2FY25. The decline was attributed to deferred export shipments, temporary softness in institutional orders, and a one-month production break in general injectables due to ongoing upgradation activities. EBITDA fell 59% to ₹2.3 crore with margins at 5.6%, while profit after tax dropped 50% to ₹2.7 crore. On a consolidated basis, revenue stood at ₹64.6 crore, down 10% year-on-year. The company secured regulatory milestones including WHO-GMP certification renewal and USFDA approval for subsidiary Innoxel Lifesciences. Despite quarterly challenges, management maintains FY26 revenue guidance of 12-14% growth and expects EBITDA margins to improve to 15-17%. The company expanded its global footprint with 36 new product registrations across multiple emerging markets including Myanmar, Afghanistan, Nigeria, Kenya, Peru, and Vietnam.